We are excited to release our latest software update with new Cyto-Mine® functionalities!

Sphere logo

 

We are excited to release our latest software update with new Cyto-Mine® functionalities!

 

The Cyto-Mine® Studio Suite contains a collection of software to allow Cyto-Mine® operation and data acquisition. The release of this updated version of the Cyto-Mine® Studio Suite brings with it a collection of improvements and new functionalities to further enhance your Cyto-Mine® workflow.

We have highlighted some of the new functionalities and their benefits below.

Pooled Picodroplet Dispensing

What is it?

Pooled Picodroplet Dispensing allows user to dispense all of the sorted picodroplets (containing selected cells of interest) into one well of a microtiter plate.

What’s the benefit?

Pooled Picodroplet Dispensing enables the dispensing of the whole sorted population (containing selected cells of interest) which is beneficial when you need a little more sample for further downstream analysis, or you would like to collect the vast majority the ‘hits’.

What’s the application?

Screening of an entire B cell population in Antibody Discovery.

The picodroplet technology of Cyto-Mine® enables the screening of millions of B cells by the encapsulation of multiple cells per picodroplet. The cells are then assayed to find antibody-secreting cells using an IgG detection assay. Pooled Picodroplet Dispensing provides the function to be able to dispense all picodroplets containing antibody-secreting cells into one well of a microtiter plate. The cells can then be released from the picodroplets and cultured overnight ready for a second round of screening on day 2 using an antigen-specific assay to detect the rare B cells of interest.

Pooled Picodroplet Dispensing allows the processing of tens of millions of cells to a small population of one or more single hit cells within 2 days.

Download Pooled Picodroplet Dispensing Protocol

 

Barcode Scanning

What is it?

Another great feature for our users, the incorporation of barcode scanning provides tracking of picodroplets and Cyto-Mine® experiments. All data from detected, sorted and dispensed picodroplets is saved in the local Cyto-Mine® database along with experiment configuration parameters and assay results, allowing centralized archiving of experimental data and improved performance of the enhanced data analysis software.

What’s the benefit?

The addition of the barcode scanner improves traceability of experiments as dispensed picodroplets are associated with their destination plate when the barcode is scanned.

Automation from Priming to Flow

What is it?

All Cyto-Mine® assays are now automatically progressed from the Cyto-Cartridge® Priming step to the end of Incubation.  Consequently, no user interaction is required during the entire Cyto-Cartridge® Priming, Picodroplet Generation and Incubation workflow.

What’s the benefit?

The automation of these stages removes the requirement for any user interaction resulting in a more streamlined, hands-off workflow.

Variable Picodroplet Generation

What is it?

During Pre-Experiment Configuration the quantity of picodroplets generated in an experiment can be selected from three options of 1 million, 1.5 million or 2 million picodroplets. 1.5 million picodroplets remains the default picodroplet generation value.

What’s the benefit?

The ability to alter the number of picodroplets generated offers users with rare precious samples the option to generate a smaller number of picodroplets or, if you have excess sample, the opportunity to increase the number of picodroplets generated to minimise the amount of unused cell sample.

 

For further information please contact:

Sphere Fluidics
Dr Zoe Nilsson
Global Product Marketing Manager
Tel: +44 (0)1223 628892
Email: Zoe.Nilsson@spherefluidics.com

 

About Sphere Fluidics www.spherefluidics.com
Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems for biologics discovery and cell line development.

Sphere Fluidics’ Cyto-Mine® System integrates selective screening of tens of millions of single cells, sorting, dispensing, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Cyto-Mine® is underpinned by the Company’s patented, microfluidic picodroplet technology.

Sphere Fluidics is located in Babraham, Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA). The Company has also internationalized its business via a global network of distributors.

Sphere Fluidics expands into additional facility at Granta Park in Cambridge, UK

Sphere logo

 

Sphere Fluidics expands into additional facility at Granta Park in Cambridge, UK

 

  • New offices at leading science hub support the Company’s rapid growth following recent investment

  • New facility is in addition to headquarters at Babraham Research Campus, Cambridgeshire, UK and offices in Monmouth Junction, New Jersey, USA

 

Cambridge, UK, 21 August 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has opened a new office space at Granta Park in Cambridgeshire, UK. The new facilities support the Company’s accelerated expansion and accommodate its plans for further growth.

Sphere Fluidics recently closed a $4.8 million USD (£3.7 million) funding round, enabling it to hire 10 new staff to expand commercial capabilities and facilitate service and support for its Cyto-Mine® Single Cell Analysis System. Sphere Fluidics sales, marketing, finance and operations teams join the specialist skills pool at Granta Park, one of the UK’s leading life-science research parks, positioned within the Cambridge Science Cluster, taking 1,038sq. ft in the McClintock Building. The Park is home to over 2,500 people and multiple organizations, placing the Company in close proximity to high-quality research and commercialization activity, and opening up the opportunity for further collaborations with potential partners, researchers and suppliers based on the campus.

Sphere Fluidics’ new facilities at Granta Park are in addition to its offices at Babraham Research Campus, Cambridgeshire, UK and Monmouth Junction, New Jersey, USA. The Company also has an established network of international distributors in Japan, France, China, Switzerland, Germany, Austria, Benelux, Australia, Scandinavia and Korea.

Rob Treanor, Director of Operations, Sphere Fluidics, commented: “Recent investment has enabled Sphere Fluidics to accelerate its plans to expand commercial and scientific activities and we are now raising further funding to invest in more new hires and increase our presence in not only the UK but also, the US. It is vital that we are positioned in locations with a flexible and innovative network and look forward to joining the collaborative culture at Granta Park to support these growth projections.”

 

Sphere Fluidics at Granta Park Cambridge

McClintock Building, Granta Park

Rob Treanor, Director of Operations, Sphere Fluidics

For further information please contact:

Sphere Fluidics
Dr Frank Craig, CEO
Tel: +44 (0)1223 628890
Email: frank.craig@spherefluidics.com

Zyme Communications
Dr Michelle Ricketts
Tel: +44 (0)7789 053885
Email: michelle.ricketts@zymecommunications.com

About Sphere Fluidics www.spherefluidics.com
Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems for biologics discovery and cell line development.

Sphere Fluidics’ Cyto-Mine® System integrates selective screening of tens of millions of single cells, sorting, dispensing, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Cyto-Mine® is underpinned by the Company’s patented, microfluidic picodroplet technology.

Sphere Fluidics is located in Babraham, Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA). The Company has also internationalized its business via a global network of distributors.

Follow Sphere Fluidics on Twitter @SphereFluidics and LinkedIn @Sphere Fluidics Limited.

About Granta Park www.grantapark.co.uk
Granta Park is Cambridge’s leading life-science research park and extends to 120 acres in total. It is a low-density research park, located at the heart of Europe’s strongest and most dynamic cluster of life science and technology-based companies.

Many of these companies were founded to commercialise research that was spun out of the UK’s top-ranked University of Cambridge which is located six miles away. The Park, with planning consent, has been developed exclusively for high-tech companies involved in research and development. Work on the green-field site for Granta Park commenced in 1998 and since that time has grown to 1 million square feet of laboratory and office space with 2,500 people working on the park each day.